Investigational drug · Phase 2
TQA2225
Also called: AP025
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-alcoholic Steatohepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 26, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TQA2225"
First trial start
2023
Sep 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQA2225", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-alcoholic Steatohepatitis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TQA2225" as an intervention, largest first.
- Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)Pivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06569524 · 120 participants (planned) · Start Sep 14, 2023 · Primary completion Dec 2026
Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg; TQA2225/AP025 or TQA2225/AP025 Placebo 50mg · For: Non-alcoholic Steatohepatitis
Sites: Lu'an, China; Beijing, China; Fuzhou, China · 53 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antibacterial efficacy of lytic phages against multidrug-resistant Pseudomonas aeruginosa infections in bacteraemia mice models.
Arumugam SN, Manohar P, Sukumaran S, et al. · BMC Microbiol 2022
Also in development for Non-alcoholic Steatohepatitis
- NNC0194-0499Phase 22 trials
Novo Nordisk · Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.